Dapagliflozin in acute myocardial infarction with type 2 diabetes: a randomized clinical trial.
A diabetes medication dramatically cut heart failure events after heart attacks in diabetic patients, addressing a gap in evidence for this specific high-risk group.
In a double-blind RCT (NCT04717986) of 181 AMI patients with type 2 diabetes randomized to dapagliflozin 10 mg or placebo over 18 months, the SGLT2 inhibitor dramatically reduced heart failure events (5.3% vs 29.5%) and improved left ventricular ejection fraction. This fills a critical evidence gap as prior trials (DAPA-MI) excluded T2D patients and showed no HF benefit in non-diabetic AMI; the T2D subgroup appears to derive substantially greater cardiac benefit.
What the study was
- Study design
- randomized_controlled_trial
- Population
- Patients with acute myocardial infarction and type 2 diabetes
- Sample size
- 181
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Curr Probl Cardiol
Why it surfaced
First dedicated RCT confirming SGLT2i benefit specifically in AMI+T2D, a clinically common and high-mortality intersection; directly extends the cardiorenal protection rationale and fills an evidence gap left by prior large trials; results are immediately actionable pending CI discrepancy verification.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.